CD5 and B-cell neoplasm: Despite its low frequency in all variants of diffuse large B-cell lymphoma (DLBCL), CD5(+) DLBCL is the most well-studied CD5+ B-cell neoplasm with poorer outcomes compared to CD5- DLBCL [34].